**Medical Technology:** 45%
**In-vitro Diagnostics:** 35%
**Hospital Information Systems:** 20%

**TOP 3 Markets:**
**China:** 40%
**USA:** 25%
**Europe:** 20%

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. generates the majority of its revenue from medical technology, followed by in-vitro diagnostics and hospital information systems. The company's largest market is China, where it generates 40% of its revenue. The USA and Europe follow with 25% and 20%, respectively, highlighting Mindray's strong international presence.

**Production Sites:**
- Shenzhen, China
- Nanjing, China
- Chengdu, China

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. mainly produces its products in China. The main production sites are located in Shenzhen, Nanjing, and Chengdu. These locations enable the company to produce efficiently and meet demand both domestically and internationally. The strategic placement of the production sites also supports logistical connections and access to qualified labor.

**Revenue growth:** 18.4% (2024)
**R&D investments:** 12% of revenue (2024)

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. pursues a growth strategy that is strongly focused on research and development (R&D). The company continuously invests a significant portion of its revenue in R&D to expand its product range and develop innovative solutions in the field of medical technology.

Another focus is on international expansion. Mindray has strengthened its presence in emerging markets while also expanding its market share in established markets. This is supported by strategic partnerships and acquisitions that expand the global distribution network and product offerings.

In addition, Mindray is focusing on digitization and automation to achieve efficiency gains and improve customer loyalty. The implementation of AI-based solutions in their products aims to optimize diagnostics and patient care.

**Main raw materials:** Electronic components, plastics, metals

**Countries of origin:** USA, Japan, Germany, South Korea

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. imports a variety of raw materials and materials necessary for the production of their medical devices. The main raw materials include electronic components, plastics, and metals. These materials are essential for the production of diagnostic and monitoring devices.

The electronic components are mainly imported from the USA, Japan, and South Korea, as these countries are leading in the production of high-quality electronic components. Plastics and metals are often sourced from Germany, which is known for its high-quality materials and advanced manufacturing technologies.

These international sources enable Mindray to produce high-quality products that meet global standards.

**Market share in China:** 30% (2024)
**Research and development ratio:** 10% of revenue (2024)
**International presence:** Active in over 190 countries (2024)

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. has a significant competitive advantage due to its strong market position in China, where it holds about 30% of the market share in the medical devices sector. This dominance is supported by continuous investments in research and development, which account for about 10% of revenue. This enables the company to develop innovative products and differentiate itself from the competition.

Furthermore, Mindray has built an extensive international presence by operating in over 190 countries. This global reach helps the company diversify risks and benefit from growth opportunities in different markets. The competitive advantage is further strengthened by a strong distribution network and strategic partnerships that facilitate access to new markets.

**Institutional investor share:** approx. 45% (2025, estimated)

**Insider purchases/sales:** No significant transactions known (2025, estimated)

The institutional investor share in Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is estimated to be around 45%. This is typical for large publicly traded companies aiming for a stable shareholder base.

Regarding insider transactions, no significant purchases or sales are known in 2025. This could indicate that the management has confidence in the current corporate strategy and does not expect any major changes in the ownership structure.

**Market share of Shenzhen Mindray Bio-Medical Electronics Co., Ltd.:** 12% (2025, estimated)

**Top competitors and their market shares:**
1. Medtronic plc - 15%
2. Siemens Healthineers AG - 14%
3. GE Healthcare - 13%
4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd. - 12%
5. Philips Healthcare - 11%
6. Abbott Laboratories - 9%
7. Johnson & Johnson - 8%
8. Becton, Dickinson and Company - 7%
9. Boston Scientific Corporation - 6%
10. Stryker Corporation - 5%

**Moat of Shenzhen Mindray:**

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. has created a significant moat through a strong focus on cost-efficient production and innovative product development. Their ability to offer high-quality medical devices at a competitive price has helped them grow strongly in emerging markets.

Compared to competitors like Medtronic or Siemens Healthineers, who have a broader product portfolio and stronger global brand presence, Mindray's moat is anchored in the price-performance strategy and rapid adaptation to market needs. While the large Western companies often benefit from their established market position and extensive research and development resources, Mindray can score points through agility and cost leadership.

However, Mindray's moat is less pronounced compared to the technological and brand-related advantages of the leading competitors. Companies like Medtronic and GE Healthcare have a more robust moat due to their long-standing market presence and innovation in certain segments.

**Revenue Growth:** 18% (2024)
**Profit Growth:** 16% (2024)
**Research and Development Ratio:** 10% of revenue (2024)

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. recorded a revenue growth of 18% and a profit growth of 16% in 2024. These growth rates indicate strong operational performance and effective cost control.

The company continues to invest significantly in research and development, accounting for 10% of revenue. This demonstrates Mindray's commitment to investing in innovative medical technologies, which can lead to long-term competitive advantages.

In addition, Mindray has expanded its market presence internationally, increasing the potential for further growth. The solid financial health and strategic focus on innovation and expansion make the stock a potentially attractive investment, especially for investors focusing on long-term growth.

**Dividend yield:** 1.5% (2025, estimated)
**Dividend history:** Continuous distribution for several years

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield is currently around 1.5%, which can be considered moderate compared to other companies in the industry.

The company has a solid financial foundation and demonstrates a reliable dividend policy. The continuous distribution in recent years indicates that Mindray aims to provide its shareholders with stable returns. Analysts expect that Mindray will continue its dividend policy in the future, provided that no unforeseen economic challenges arise.